Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eisai

Real World Study Tracked Lecanemab Outcomes Three Years After Approval Across Diverse United States Clinical Settings

Eisai's LEADER study reported that 83% of early Alzheimer's patients were stable or improved on Leqembi. Here is what a retrospective abstract can establish.

Medical Daily

FDA Approves Weekly At-Home Injection of Leqembi for Alzheimer's Patients Starting Treatment

FDA approved LEQEMBI IQLIK on July 13, 2026, a weekly at-home autoinjector for early Alzheimer's patients. Here's what it means and what patients should know.

Medical Daily

Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish

Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA Extends Review of Eisai, Biogen Alzheimer's Drug

The agency pushed its decision on weekly subcutaneous LEQEMBI IQLIK for early Alzheimer's initial treatment to Aug. 24 after seeking additional information.

International Business Times

NHS watchdog to review evidence on two pioneering Alzheimer’s drugs

Donanemab and lecanemab were licensed for use in the UK in 2024 but were not made available on the NHS after Nice deemed their benefits “too small” to justify the cost

The Independent UK

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

On Tuesday, Merck Co. Inc. (NYSE:MRK) and Eisai shared topline data from the Phase 3 LITESPARK-011 trial of the dual oral regimen of Welireg (belzutifan) plus Lenvima (lenvatinib).

Benzinga

What is lecanemab, the newly approved Alzheimer’s drug? Can it really slow down dementia?

Dementia is a condition that results in progressive memory or thinking problems. It’s now the most common cause of death in Australia. There are many different causes of dementia, but Alzheimer’s disease accounts for around 60–80% of all cases.

The Conversation

Read news from The Economist, FT, and more,
with one subscription

The real reason two ‘miracle’ Alzheimer’s drugs were rejected for NHS use

ANALYSIS: Paul Atkinson and Sally Sheard say the decision reflects a cautious and evidence-based approach that protects patients and public funds

The Independent UK

Why Nice was right to say no – for now – to new Alzheimer’s drugs

The UK’s National Institute for Health and Care Excellence (Nice) has declined to recommend two new Alzheimer’s drugs for routine NHS use in England. While disappointing for some families affected by dementia, this decision reflects a cautious and evidence-based approach that protects patients and public funds.

The Conversation

European regulators OK Alzheimer's treatment Leqembi after initial doubts

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer

The Independent UK

European committee takes a second look at Alzheimer's drug and now says it should be approved

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

The Independent UK

Revolution Or Mirage? Controversy Surrounds New Alzheimer's Drugs

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.

International Business Times

What you need to know about lecanemab – the Alzheimer’s drug rejected for NHS use

The drug has been developed by Eisai, a Japanese pharmaceutical company, and is sold under the brand name Leqembi

The Independent UK

What is Lecanemab and who makes it? Alzheimer’s drug gets approval but will not be available on the NHS

NICE says drug is not cost effective and shares fears of side effects

Evening Standard

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

First drug to slow Alzheimer’s progression will not be made available on the NHS

The spending watchdog has recommended that a drug shown to slow the progression of Alzheimer’s disease should not be rolled out on the NHS.

The Independent UK

FDA approves a second Alzheimer's drug that can modestly slow disease

U.S. health officials have approved a new Alzheimer’s drug that can modestly slow the disease

International Business Times

Highly Awaited Alzheimer's Drug Hit By Delays

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

The Independent UK

After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Insurers won't cover new Alzheimer's treatment for some customers

Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients

Tribune News Service

Lilly applies for Alzheimer’s drug’s US approval after trial success

Eli Lilly & Co. said it applied for full U.S. approval of its Alzheimer’s disease drug that’s expected to compete with Eisai Co.’s Leqembi as the U.S. drugmaker revealed details of a final-stage trial at a conference in Amsterdam.

Tribune News Service

New Alzheimer’s drug is first to show it slows disease. But It’s facing a rocky rollout

Eisai Co.’s breakthrough Alzheimer’s drug — the first to show it slows the brain-destroying disease — is facing a rocky rollout as doctors grapple with logistical issues, insurance uncertainties and complicated safety testing requirements.

The Guardian - UK

New dementia drugs: patients to pay privately or face NHS postcode lottery

As advanced remedies emerge, the chief executive of Alzheimer’s Research UK warns sufferers could miss out as the health service struggles to cope

Daily Mirror

Miracle new Alzheimer's drug which slows cognitive decline of disease to be rolled out

The Food and Drug Administration (FDA) has approved the much awaited drug Leqembi which has been shown to slow the cognitive decline caused by Alzheimer’s, the most common type of dementia

Al Jazeera

US government approves Alzheimer’s drug to slow cognitive decline

Some insurances, including the government-run Medicare, refused to pay for the drug until it received full approval.

Tribune News Service

Eisai Alzheimer's drug gets full US approval, widening access to the therapy

Eisai Co.’s Alzheimer’s drug Leqembi gained full approval from U.S. regulators Thursday, a move expected to widen access to the first drug cleared based on its ability to slow progression of the mind-robbing disease.

1 2 3 4

People

Chiquita BrooksLaSure

14 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

Alzheimer Research UK

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.